is not clear, use caution. Use Caution/Monitor.dosulepintrifluoperazine and dosulepin both increase sedation. Use Caution/Monitor.doxepintrifluoperazine and doxepin both increase sedation. Use Caution/Monitor.doxylaminedoxylamine and trifluoperazine both increase sedation. Use Caution/Monitor.droperidoldroperidol and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.droperidol and trifluoperazine both increase sedation. Use Caution/Monitor.efavirenzefavirenz and trifluoperazine both decrease QTc interval. Use Caution/Monitor.eletriptaneletriptan, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).eliglustateliglustat and trifluoperazine both decrease QTc interval. Use Caution/Monitor.encorafenibencorafenib and trifluoperazine both decrease QTc interval. Use Caution/Monitor.entrectinibentrectinib and trifluoperazine both decrease QTc interval. Use Caution/Monitor.ephedrinetrifluoperazine increases and ephedrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, ephedrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.epinephrinetrifluoperazine increases and epinephrine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, epinephrine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.trifluoperazine decreases effects of epinephrine by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia.epinephrine racemictrifluoperazine increases and epinephrine racemic decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine decreases effects of epinephrine racemic by pharmacodynamic antagonism. Use Caution/Monitor. Block pressor response to epinephrine, which may result in severe hypotension and tachycardia.ergoloid mesylatesergoloid mesylates, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).ergotamineergotamine, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).eribulineribulin and trifluoperazine both decrease QTc interval. Use Caution/Monitor.esketamine intranasalesketamine intranasal, trifluoperazine. Either increases toxicity of the other by sedation. Modify Therapy/Monitor Closely.estazolamestazolam and trifluoperazine both increase sedation. Use Caution/Monitor.ethanoltrifluoperazine and ethanol both increase sedation. Use Caution/Monitor.etomidateetomidate and trifluoperazine both increase sedation. Use Caution/Monitor.fenfluraminetrifluoperazine increases and fenfluramine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, fenfluramine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.fentanylfentanyl, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).fesoterodinefesoterodine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.fesoterodine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of fesoterodine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.fexinidazolefexinidazole will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP1A2 metabolism. Use Caution/Monitor.fingolimodfingolimod and trifluoperazine both decrease QTc interval. Use Caution/Monitor.flavoxateflavoxate decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.flavoxate decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of flavoxate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.flecainidetrifluoperazine and flecainide both increase QTc interval. Modify Therapy/Monitor Closely.flibanserinflibanserin, trifluoperazine. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).fluoxetinefluoxetine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.trifluoperazine and fluoxetine both increase QTc interval. Modify Therapy/Monitor Closely.fluphenazinefluphenazine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.fluphenazine and trifluoperazine both increase sedation. Use Caution/Monitor.flurazepamflurazepam and trifluoperazine both increase sedation. Use Caution/Monitor.fluvoxaminefluvoxamine and trifluoperazine both increase QTc interval. Modify Therapy/Monitor Closely.formoteroltrifluoperazine increases and formoterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.foscarnettrifluoperazine and foscarnet both increase QTc interval. Modify Therapy/Monitor Closely.frovatriptanfrovatriptan, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).ganaxolonetrifluoperazine and ganaxolone both increase sedation. Use Caution/Monitor.gemifloxacingemifloxacin and trifluoperazine both decrease QTc interval. Use Caution/Monitor.gilteritinibgilteritinib and trifluoperazine both decrease QTc interval. Use Caution/Monitor.glycopyrrolatetrifluoperazine increases effects of glycopyrrolate by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.glycopyrrolate inhaledglycopyrrolate inhaled decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.glycopyrrolate inhaled decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of glycopyrrolate inhaled by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.glycopyrronium tosylate topicalglycopyrronium tosylate topical, trifluoperazine. Either increases effects of the other by pharmacodynamic synergism. Use Caution/Monitor. Coadministration of glycopyrronium tosylate topical with other anticholinergic medications may result in additive anticholinergic adverse effects.granisetrongranisetron and trifluoperazine both decrease QTc interval. Use Caution/Monitor.guanfacineguanfacine, trifluoperazine. Mechanism: pharmacodynamic synergism. Use Caution/Monitor. Additive hypotensive effects; potential delirium.haloperidolhaloperidol and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.haloperidol and trifluoperazine both increase sedation. Use Caution/Monitor.henbanehenbane decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.henbane decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of henbane by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.homatropinehomatropine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.homatropine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of homatropine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hydromorphonehydromorphone and trifluoperazine both increase sedation. Use Caution/Monitor.hydroxyzinehydroxyzine and trifluoperazine both increase sedation. Use Caution/Monitor.hydroxyzine and trifluoperazine both decrease QTc interval. Use Caution/Monitor.hyoscyaminehyoscyamine decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.hyoscyamine decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of hyoscyamine by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hyoscyamine spraytrifluoperazine increases effects of hyoscyamine spray by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.hyoscyamine spray decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.hyoscyamine spray decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.iloperidoneiloperidone and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.trifluoperazine and iloperidone both increase QTc interval. Modify Therapy/Monitor Closely.iloperidone and trifluoperazine both increase sedation. Use Caution/Monitor.imipraminetrifluoperazine and imipramine both increase sedation. Use Caution/Monitor.incobotulinumtoxinAtrifluoperazine increases effects of incobotulinumtoxinA by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.indacaterol, inhaledindacaterol, inhaled, trifluoperazine. QTc interval. Use Caution/Monitor. Drugs that are known to prolong the QTc interval may have an increased the risk of ventricular arrhythmias.insulin degludectrifluoperazine decreases effects of insulin degludec by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.insulin degludec/insulin asparttrifluoperazine decreases effects of insulin degludec/insulin aspart by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.insulin inhaledtrifluoperazine decreases effects of insulin inhaled by Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase blood glucose concentrations.ipratropiumipratropium decreases levels of trifluoperazine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor.ipratropium decreases levels of trifluoperazine by pharmacodynamic antagonism. Use Caution/Monitor.trifluoperazine increases effects of ipratropium by pharmacodynamic synergism. Use Caution/Monitor. Additive anticholinergic effects, possible hypoglycemia.isofluraneisoflurane and trifluoperazine both decrease QTc interval. Use Caution/Monitor.isoproterenoltrifluoperazine increases and isoproterenol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, isoproterenol. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.ketamineketamine and trifluoperazine both increase sedation. Use Caution/Monitor.ketotifen, ophthalmictrifluoperazine and ketotifen, ophthalmic both increase sedation. Use Caution/Monitor.lapatinibtrifluoperazine and lapatinib both increase QTc interval. Modify Therapy/Monitor Closely.lasmiditanlasmiditan, trifluoperazine. Either increases effects of the other by sedation. Use Caution/Monitor. Coadministration of lasmiditan and other CNS depressant drugs, including alcohol have not been evaluated in clinical studies. Lasmiditan may cause sedation, as well as other cognitive and/or neuropsychiatric adverse reactions.lemborexantlemborexant, trifluoperazine. Either increases effects of the other by sedation. Modify Therapy/Monitor Closely. Dosage adjustment may be necessary if lemborexant is coadministered with other CNS depressants because of potentially additive effects.levalbuteroltrifluoperazine increases and levalbuterol decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.levofloxacintrifluoperazine and levofloxacin both increase QTc interval. Modify Therapy/Monitor Closely.levomilnacipranlevomilnacipran, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).levorphanollevorphanol and trifluoperazine both increase sedation. Use Caution/Monitor.linezolidlinezolid, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).liraglutidetrifluoperazine, liraglutide. Other (see comment). Use Caution/Monitor. Comment: Phenothiazines may increase or decrease glucose levels, monitor therapy closely when these agents are concurrently administered.lisdexamfetaminetrifluoperazine increases and lisdexamfetamine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.trifluoperazine, lisdexamfetamine. Mechanism: unknown. Use Caution/Monitor. Risk of cardiac arrhythmia or sudden death, more likely w/thioridazine than other phenothiazines. Interaction more likely in certain predisposed pts. only.lithiumlithium, trifluoperazine. Other (see comment). Use Caution/Monitor. Comment: Risk of neurotoxicity. Multiple mechanisms involved.lithium, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).lithium and trifluoperazine both decrease QTc interval. Use Caution/Monitor.lofepraminetrifluoperazine and lofepramine both increase sedation. Use Caution/Monitor.lofexidinetrifluoperazine and lofexidine both increase sedation. Use Caution/Monitor.loprazolamloprazolam and trifluoperazine both increase sedation. Use Caution/Monitor.lorazepamlorazepam and trifluoperazine both increase sedation. Use Caution/Monitor.lorcaserinlorcaserin, trifluoperazine. unspecified interaction mechanism. Use Caution/Monitor. Serotonin modulators may enhance dopamine blockade, possibly increasing the risk for neuroleptic malignant syndrome. Antipsychotics may enhance serotonergic effect of serotonin modulators, which may result in serotonin syndrome. Monitor for evidence of serotonin toxicity (eg, mental status changes, autonomic instability, and neuromuscular hyperactivity) or neuroleptic malignant syndrome (eg, hyperthermia, muscle rigidity, autonomic dysfunction).lormetazepamlormetazepam and trifluoperazine both increase sedation. Use Caution/Monitor.loxapineloxapine and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.loxapine and trifluoperazine both increase sedation. Use Caution/Monitor.loxapine inhaledloxapine inhaled and trifluoperazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor.loxapine inhaled and trifluoperazine both increase sedation. Use Caution/Monitor.lumefantrinelumefantrine will increase the level or effect of trifluoperazine by affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor.lurasidonelurasidone, trifluoperazine. Either increases toxicity of the other by Other (see comment). Use Caution/Monitor. Comment: Potential for increased CNS depressant effects when used concurrently; monitor for increased adverse effects and toxicity.maprotilinetrifluoperazine and maprotiline both increase sedation. Use Caution/Monitor.marijuanatrifluoperazine and marijuana both increase sedation. Use Caution/Monitor.meclizinemeclizine decreases levels of trifluoperazine by inhibition of GI